Objective: The objective of this study was to clarify the efficacy and safety of factor Xa inhibitors for antiphospholipid syndrome patients in real world utilization. Methods: This is a retrospective cohort study comprised of all consecutive patients with antiphospholipid syndrome in our department over a period of 28 years. Patients treated with factor Xa inhibitors were extracted from the cohort. As a control group, patients treated with warfarin were selected from the same cohort with matched age, gender, coexistence of systemic lupus erythematosus, and the presence of antiplatelet therapy, after which we used a propensity score for each of the risk factors as an additional covariate in multivariate Cox proportional hazard regression. The primary endpoint was set as thrombotic and hemorrhagic event-free survival for five years. Results: Among 206 patients with antiphospholipid syndrome, 18 had a history of anti-Xa therapy (five rivaroxaban, 12 edoxaban, one apixaban). Fourteen out of 18 patients on anti-Xa therapy had switched to factor Xa inhibitors from warfarin. Event-free survival was significantly shorter during anti-Xa therapy than that during warfarin therapy (hazard ratio: 12.1, 95% confidence interval: 1.73-248, p ¼ 0.01) (Figure 1(a) ). Similarly, event-free survival in patients treated with factor Xa inhibitors was significantly shorter compared with controls (hazard ratio: 4.62, 95% confidence interval: 1.54-13.6, p ¼ 0.0075). In the multivariate Cox proportional hazard model, event-free survival in patients with anti-Xa therapy remained significantly shorter (hazard ratio: 11.9, 95% confidence interval: 2.93-56.0, p ¼ 0.0005). Conclusions: Factor Xa inhibitors may not be recommended for antiphospholipid syndrome. Lupus (2019) 28, 1577-1582.
Introduction
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL) with clinical manifestations of arterial thrombosis, venous thrombosis, and/or pregnancy morbidity. According to the guidelines on the investigation and management of APS published in 2012, 1 the gold standard for the secondary prevention of thrombosis is warfarin. However, the preventive outcome of warfarin therapy has not been satisfactory yet in APS patients. 2 Since warfarin treatment requires maintaining the prothrombin time-international normalized ratio (PT-INR) between the therapeutic and safety ranges, clinicians have to take into account possible drug interactions and educate patients to avoid certain foods high in vitamin K, thus complicating the patient's daily life.
Factor Xa inhibitors are effective and safe alternatives to warfarin in patients with atrial fibrillation and venous thromboembolism. Factor Xa inhibitors showed equivalent efficacy to warfarin in inhibiting thrombin generation in non-APS patients with venous thromboembolism. 3 To clarify whether factor Xa inhibitors would be an effective and safe alternative to warfarin in APS, two randomized controlled trials (RCT) have been conducted. In the Rivaroxaban in APS (RAPS) trial, 54 APS patients treated with rivaroxaban were compared with 56 treated with warfarin. The primary endpoint was set as thrombin generation on day 42 and the secondary endpoints as occurrence of thromboembolism and/or bleeding events up to day 210. Since no thrombotic events were documented during the study period, the authors stated that there was no increased thrombotic risk in patients treated with rivaroxaban compared to warfarin users, even though the patients treated with rivaroxaban had a significant increased thrombin generation as the surrogate marker of thrombotic tendency. 4 On the contrary, the Trial on Rivaroxaban in Antiphospholipid Syndrome (TRAPS) showed that thrombotic or bleeding events occurred more frequently in the rivaroxaban group than in the warfarin group. 5 The trial was terminated prematurely because of an excess of events among patients in the rivaroxaban arm. TRAPS included only high-risk APS patients with triple positive for criteria aPL (lupus anticoagulant, anticardiolipin, and anti-b2-glycoprotein I antibodies of the same isotype), thus the subjects in this trial do not represent the general APS population. Knowing the limitations of these two RCT, real world evidence of factor Xa inhibitors for APS has not been established yet. To explore the clinical relevance of factor Xa inhibitors for APS patients in general clinical settings, we conducted this retrospective cohort study.
Patients and methods

Study design and approval
This is a single-center retrospective cohort study conducted at the Rheumatology department in Hokkaido University Hospital. This study was executed in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and approved by Hokkaido University Hospital ethics committee (approval number: 018-0136). Participants provided informed consent verbally.
Patients
The cohort comprised consecutive patients who were diagnosed as APS between April 1990 and March 2018 in our Rheumatology department. The attending physicians and authors verified the diagnosis of APS according to the Sydney-revised Sapporo criteria 6 for definite APS. The coexistence of systemic lupus erythematosus (SLE) was diagnosed according to the American College of Rheumatology (ACR) revised criteria. 7 Patients treated with factor Xa inhibitors were extracted from the cohort. As controls, patients treated with warfarin were selected from the same cohort at 1:2 with matched age, gender, coexistence of SLE, and the presence of antiplatelet therapy.
Endpoint and variables
The primary endpoint was set as event-free survival for five years. An event was defined as recurrence of arterial/venous thrombosis and severe bleeding requiring hospitalization and/or blood transfusion. Arterial/venous thrombosis and bleeding were diagnosed by angiography, ultrasonography, computed tomography scan, and/or magnetic resonance imaging.
All potential confounding factors associated with arterial/venous thrombosis or bleeding events were recorded at the time of treatment exposure. The confounding factors included hypertension, diabetes mellitus, dyslipidemia, smoking, obesity, chronic kidney disease (CKD), initial manifestations of APS (arterial thrombosis and venous thrombosis), aPL profile, and use of corticosteroids. Hypertension was defined as the use of any antihypertensive medication or blood pressure higher than 140/90 mmHg on more than two occasions during the follow-up period. Diabetes mellitus was defined as the use of any antidiabetic medication or hemoglobin A1c >6.5%. Dyslipidemia was defined as the use of any lipid-lowering agents, serum low-density lipoprotein concentration >140 mg/dL, high-density lipoprotein concentration < 40 mg/dL, or triglyceride >150 mg/dL. Current cigarette smoking was defined as any cigarette or cigar during the follow-up period. Obesity was defined as a body mass index >25, and CKD as an estimated glomerular filtration rate < 45 mL/min.
Determination of antiphospholipid antibodies and antiphospholipid score
IgG or IgM anticardiolipin antibodies, 8 IgG or IgM anti-beta2 glycoprotein I antibodies, 9 IgG or IgM phosphatidylserine-dependent anti-prothrombin antibody 10 were assayed by enzyme-linked immunosorbent assay as described previously.
For the detection of lupus anticoagulant, the guidelines recommended by the Subcommittee for Standardization of the International Society on Thrombosis and Haemostasis were followed. 8 The antiphospholipid score (aPL-S), a quantitative marker that represents aPL profile, was calculated in each patient as described previously. 9
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An aPL-S more than 30 indicates a high risk of developing thrombosis.
Statistical analysis
Categorical variables described as counts and percentages were compared with Fisher's exact test. Continuous variables were expressed as the mean AE standard deviation and were assessed using a t test. Event-free survival was estimated by the Kaplan-Meier method, and all potential confounding factors were assessed using the univariate and multivariate Cox proportional hazard models. Because of the relatively few patients treated with factor Xa inhibitors, a propensity score was used for each of the risk factors as an additional covariate in the multivariate Cox proportional hazard regression. The distribution of propensity scores for determining the probability of taking factor Xa inhibitors and the Concordance statistic are shown in Supplementary Figure 1 . The distributions of confounding covariates between the groups are shown in Supplementary Figure 2 .
In all statistical analyses, p < 0.05 was taken to indicate statistical significance. All statistical analyses were performed using JMP Õ Pro 12.2.0 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Patients' profile
The cohort comprised 206 patients with APS. (52.8%) had high aPL-S more than 30. The percentage of patients with triple positivity and prevalence of patients with high aPL-S were not significantly different between the two groups. Patients on warfarin treatment had a significantly greater proportion with a history of arterial thrombosis (72.2% versus 44.4%, p ¼ 0.0463).
Comparison between factor Xa inhibitors and warfarin in the same patients
Fourteen out of 18 patients on anti-Xa therapy had switched to factor Xa inhibitors from warfarin because the patients wished to avoid restrictions around food containing a lot of vitamin K. Thus, first, we compared the endpoint between warfarin therapy period and anti-Xa therapy period in each of the 14 patients using the Cox proportional hazard model. The intensity of warfarin level was controlled at a PT-INR between 2.0 and 3.0. Patients' characteristics at the initiation of each drug are summarized in Supplementary Table 1 . There was no statistically significant difference between the backgrounds in each group. Event-free survival was significantly shorter during anti-Xa therapy than that during warfarin therapy (Figure 1(a) ). Considering the fact that the patients were inevitably younger on warfarin therapy because all initially used warfarin and then switched to anti-Xa therapy, we used the multivariate Cox proportional hazard model including age as a covariate and found that anti-Xa therapy was still associated with a hazard ratio of 14.0 (95% CI: 1.76-306, p ¼ 0.0108). Recurrences of thrombosis were observed in one patient (1.92/100 person-years) during the warfarin therapy period and in four patients (18.5/100 person-years) during anti-Xa therapy, respectively. The details of thrombosis were branch retinal vein occlusion during warfarin therapy and two each for cerebral infarction and deep vein thrombosis during anti-Xa therapy. There were no severe bleeding events during warfarin therapy whereas subarachnoid hemorrhage was observed in one patient (4.62/100 person-years) during anti-Xa therapy. The aPL-S was not significantly different between the warfarin (37.5 AE 4.96) and anti-Xa (32.5 AE 5.61, p ¼ 0.51) therapy periods.
Comparison between patients treated with factor Xa inhibitors and those treated with warfarin
Next, we compared the endpoint between 18 patients treated with factor Xa inhibitors and 36 patients treated with warfarin. There were six (21.4/100 person-years) and eight (5.50/100 person-years) cases of recurrences of thrombosis in the factor Xa inhibitors and warfarin groups, respectively. For detailed information about the thrombosis, four patients had cerebral infarction and two patients developed deep vein thrombosis in the factor Xa inhibitors group. In the warfarin group, five cases of cerebral infarction, one case of deep vein thrombosis, one case of amaurosis fugax, and one case of transient ischemic attack were observed. On the other hand, severe bleeding events were observed in one patient (3.56/100 person-years) in the factor Xa inhibitors group and in two patients (1.32/100 person-years) in the warfarin group. The former was subarachnoid hemorrhage and the latter cerebellar hemorrhage and diverticular bleeding. Event-free survival of the patients treated with factor Xa inhibitors was significantly shorter than that of patients in the warfarin group (Figure 1(b) ). All potential confounding factors were assessed using the univariate and multivariate Cox proportional hazard models ( Table 2 ). In the univariate Cox proportional hazard model, factor Xa inhibitors were significantly associated with the events. In the multivariate Cox proportional hazard model, factor Xa inhibitors were still significantly associated with the events. It turned out that patients with a history of venous thrombosis have a lower risk of events.
Discussion
We firstly assessed the clinical efficacy of factor Xa inhibitors for APS patients in real world utilization and showed that event-free survival was significantly shorter during anti-Xa therapy than that during warfarin therapy in our cohort. This study provided further additional information as follows:
(1) longitudinal efficacy and safety up to five years;
(2) data of heterogeneous APS patients; and (3) the use of rivaroxaban, edoxaban, and apixaban. Factor Xa inhibitors have been proposed as a potential alternative treatment for APS patients unless the patients are at high risk of thrombosis, such as triple aPL positivity or high aPL-S. 4, 10, 11 The TRAPS study showed that rivaroxaban led to more frequent thrombotic or bleeding events only in APS patients with triple positivity of criteria aPL. 5 However, in our study including all APS patients other than triple positivity, anti-Xa therapy showed poor event-free survival as well. Some case reports and case series reported the use of factor Xa inhibitors in APS patients, 10, 11 and several authors have documented thrombosis recurrence after switching from warfarin to factor Xa inhibitors. 12 15 These studies, even considering the limitation of lacking a comparator arm, suggest that switching from warfarin to factor Xa inhibitors might lead to an increase in relapse of thrombosis. Consistent with these case reports, our study showed a significant lower event-free survival during anti-Xa therapy compared with warfarin therapy in real world utilization.
Our patients in the warfarin group had a significantly greater proportion with a history of arterial thrombosis than those in the anti-Xa therapy group, suggesting that our patients treated with warfarin might be at a higher risk of thrombosis. In other words, anti-Xa therapy still had a poor event-free survival in patients with a lower risk of thrombosis. The hazard ratio increased after adjustment for confounding factors which could contribute to the risk of thrombosis.
We acknowledge some limitations in our study. First, the number of patients treated with factor Xa inhibitors was small. Second, the study was conducted in a single center. Third, our study was performed as a retrospective design, although the patients were regularly followed-up. Due to these limitations, it will be difficult to reach a strong conclusion regarding the efficacy and safety of factor Xa inhibitors for APS patients in real world utilization.
In conclusion, our findings could suggest that factor Xa inhibitors for heterogeneous APS may not be recommended. Prospective large-scale and longterm studies are required to evaluate the efficacy and safety of factor Xa inhibitors in APS patients. 
